Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

Expectations of rate cuts boost NZ sharemarket in light trade
Markets Market close

Expectations of rate cuts boost NZ sharemarket in light trade

There were 89 rises and 48 falls on the main board.

Jamie Gray 02 Jul 2025
Smart CEO Anna Scott resigns
Markets

Smart CEO Anna Scott resigns

Anna Scott will take up her new role on October 1.

Staff reporters 02 Jul 2025
Forsyth Barr highlights 'hidden gem' at Ebos
Markets

Forsyth Barr highlights 'hidden gem' at Ebos

Both businesses were part of its A$1.16b LifeHealthcare acquisition.

Rebecca Howard 02 Jul 2025